GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » ROE %

LTR Pharma (ASX:LTP) ROE % : -25.83% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. LTR Pharma's annualized net income for the quarter that ended in Dec. 2024 was A$-4.81 Mil. LTR Pharma's average Total Stockholders Equity over the quarter that ended in Dec. 2024 was A$18.62 Mil. Therefore, LTR Pharma's annualized ROE % for the quarter that ended in Dec. 2024 was -25.83%.

The historical rank and industry rank for LTR Pharma's ROE % or its related term are showing as below:

ASX:LTP' s ROE % Range Over the Past 10 Years
Min: -236.45   Med: -236.45   Max: -47.02
Current: -47.02

During the past 1 years, LTR Pharma's highest ROE % was -47.02%. The lowest was -236.45%. And the median was -236.45%.

ASX:LTP's ROE % is ranked worse than
54.2% of 1321 companies
in the Biotechnology industry
Industry Median: -40.59 vs ASX:LTP: -47.02

LTR Pharma ROE % Historical Data

The historical data trend for LTR Pharma's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma ROE % Chart

LTR Pharma Annual Data
Trend Jun24
ROE %
-236.45

LTR Pharma Semi-Annual Data
Dec23 Jun24 Dec24
ROE % -80.80 -191.56 -25.83

Competitive Comparison of LTR Pharma's ROE %

For the Biotechnology subindustry, LTR Pharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LTR Pharma's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's ROE % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's ROE % falls into.


;
;

LTR Pharma ROE % Calculation

LTR Pharma's annualized ROE % for the fiscal year that ended in Jun. 2024 is calculated as

ROE %=Net Income (A: Jun. 2024 )/( (Total Stockholders Equity (A: . 20 )+Total Stockholders Equity (A: Jun. 2024 ))/ count )
=/( (+)/ )
=/
= %

LTR Pharma's annualized ROE % for the quarter that ended in Dec. 2024 is calculated as

ROE %=Net Income (Q: Dec. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Dec. 2024 ))/ count )
=-4.81/( (2.941+34.299)/ 2 )
=-4.81/18.62
=-25.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2024) net income data. ROE % is displayed in the 30-year financial page.


LTR Pharma  (ASX:LTP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-4.81/18.62
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.81 / 0.126)*(0.126 / 19.0505)*(19.0505 / 18.62)
=Net Margin %*Asset Turnover*Equity Multiplier
=-3817.46 %*0.0066*1.0231
=ROA %*Equity Multiplier
=-25.2 %*1.0231
=-25.83 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-4.81/18.62
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-4.81 / -4.81) * (-4.81 / -5.56) * (-5.56 / 0.126) * (0.126 / 19.0505) * (19.0505 / 18.62)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.8651 * -4412.7 % * 0.0066 * 1.0231
=-25.83 %

Note: The net income data used here is two times the semi-annual (Dec. 2024) net income data. The Revenue data used here is two times the semi-annual (Dec. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


LTR Pharma ROE % Related Terms

Thank you for viewing the detailed overview of LTR Pharma's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


LTR Pharma Business Description

Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.

LTR Pharma Headlines

No Headlines